Complementary & Alternative Medicine

FDA extends review period for chromium picolinate diabetes-related health claims

Published in Obesity and Diabetes Week, September 12th, 2005

The U.S. Food and Drug Administration (FDA) has requested an extension for the review of Nutrition 21, Inc.'s, (NXXI) qualified health claim petition associating chromium picolinate with a reduced risk of insulin resistance, type 2 diabetes, and related diseases.

The company has agreed to the extension.

Nutrition 21 is a nutritional bioscience company and the maker of chromium-based supplements with health benefits substantiated, according to the company, by clinical research.

The company markets Chromax chromium picolinate, which is the most-studied form of the essential mineral chromium. Nutrition 21 holds 36 patents for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2005-09-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry